Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dimethylcurcumin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.78 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.78 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | GSK3B | P49841 | 3/20 | 0.70 |
| ▸ | BACE1 | P56817 | 2/20 | 0.69 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.65 |
| ▸ | JUN | P05412 | 3/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | FOS | P01100 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylcurcumin SCHEMBL3686107 | 1.00 | HDAC1 (0.78) | HDAC1HDAC2HDAC8KDM4EALDH1A1 | |
| Dimethylcurcumin SCHEMBL3487105 | 1.00 | HDAC1 (0.78) | HDAC1HDAC2HDAC8KDM4EALDH1A1 | |
| Dimethylcurcumin SCHEMBL29354872 | 1.00 | HDAC1 (0.78) | HDAC1HDAC2HDAC8KDM4EALDH1A1 | |
| SCHEMBL14112832 | 0.93 | HDAC1 (0.69) | HDAC1HDAC2HDAC8KDM4EALDH1A1 | |
| SCHEMBL16888009 | 0.93 | GSK3B (0.81) | HDAC1HDAC2HDAC8KDM4EALDH1A1 | |
| Dimethylcurcumin SCHEMBL2528943 | 0.93 | HDAC1 (0.69) | HDAC1HDAC2HDAC8KDM4EALDH1A1 | |
| Dimethylcurcumin SCHEMBL2528940 | 0.93 | HDAC1 (0.69) | HDAC1HDAC2HDAC8KDM4EALDH1A1 | |
| Methylcurcumin SCHEMBL9907002 | 0.93 | GSK3B (0.81) | HDAC1HDAC2HDAC8KDM4EALDH1A1 | |
| SCHEMBL21743109 | 0.93 | HDAC1 (0.71) | HDAC1HDAC2HDAC8KDM4EALDH1A1 | |
| SCHEMBL9907006 | 0.92 | HDAC1 (0.67) | HDAC1HDAC2HDAC8KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114903902-A | Application of GnRH receptor antagonist and androgen receptor antagonist in preparation of medicine for treating prostatic cancer | 江苏恒瑞医药股份有限公司 | 2022-08-16 | — | — | CN | claimed |
| US-20180008557-A1 | USE OF TWO BOTANICALS WITH COMPLEMENTARY ACTIVITIES FOR IMPROVEMENT OF SKIN | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-01-11 | — | — | US | claimed |
| US-20100105644-A1 | BOTANICAL COMPOSITION FOR ENHANCED SKIN REPAIR AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-04-29 | — | — | US | claimed |
| US-20100048676-A1 | Non-androgen dependent roles for androgen receptor in liver cancer | UNIVERSITY OF ROCHESTER (US) | 2010-02-25 | — | — | US | claimed |
| US-12630883-B2 | Test method of dividing blastic plasmacytoid dendritic cell neoplasm (BPDCN) into subtypes | JAPANESE FOUNDATION FOR CANCER RESEARCH (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20250339385-A1 | TOPICAL FORMULATION OF DIMETHYLCURCUMIN | Annji Pharmaceutical Co., Ltd. (TW) | 2025-11-06 | — | — | US | disclosed |
| US-12303470-B2 | Method and composition for selective treatment of androgen receptors | SKINQRI, LLC (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4330222-A4 | TOPICAL FORMULATION OF DIMETHYLCURCUMIN | Annji Pharmaceutical Co., Ltd. (TW) | 2025-04-09 | — | — | EP | disclosed |
| EP-3413045-B1 | DIAGNOSIS MARKER FOR RARE HEMATOPOIETIC TUMOR, TEST METHOD, THERAPEUTIC AGENT, AND SCREENING METHOD | JAPANESE FOUND FOR CANCER RES (JP) | 2024-04-03 | — | — | EP | disclosed |
| EP-4330222-A1 | TOPICAL FORMULATION OF DIMETHYLCURCUMIN | Annji Pharmaceutical Co., Ltd. (TW) | 2024-03-06 | — | — | EP | disclosed |
| US-11802113-B2 | Substituted pyrazole compounds, compositions containing same, and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2023-10-31 | — | — | US | disclosed |
| US-20230323475-A1 | TEST METHOD, OF DIVIDING BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) INTO SUBTYPES | JAPANESE FOUNDATION FOR CANCER RESEARCH (JP) | 2023-10-12 | — | — | US | disclosed |
| EP-1804806-A2 | METHODS AND COMPOSITIONS FOR ENHANCING DEGRADATION OF NUCLEAR RECEPTOR TRANSCRIPTION FACTORS AND USES THEREOF | AndroScience Corporation (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1765346-A2 | ENHANCEMENT OF ANTI-ANDROGENIC ACTIVITY BY A COMBINATION OF INHIBITORS TARGETING DIFFERENT STEPS OF A STEROID-DEPENDENT GENE ACTIVATION PATHWAY AND USES THEREOF | AndroScience Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060084704-A1 | Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof | ANDROSCIENCE CORPORATION | 2006-04-20 | — | — | US | disclosed |
| WO-2006029040-A2 | METHODS AND COMPOSITIONS FOR ENHANCING DEGRADATION OF NUCLEAR RECEPTOR TRANSCRIPTION FACTORS AND USES THEREOF | SHIH CHARLES C Y (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20050209205-A1 | Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof | ANDROSCIENCE CORPORATION | 2005-09-22 | — | — | US | disclosed |
| WO-2005072462-A2 | ENHANCEMENT OF ANTI-ANDROGENIC ACTIVITY BY A COMBINATION OF INHIBITORS TARGETING DIFFERENT STEPS OF A STEROID-DEPENDENT GENE ACTIVATION PATHWAY AND USES THEREOF | SHIH CHARLES (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209205-A1 | Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof | NR5A1, CYP17A1, ESRRB | HDAC1 548/4885HDAC2 1274/4885HDAC8 174/4885 |
| US-20180008557-A1 | USE OF TWO BOTANICALS WITH COMPLEMENTARY ACTIVITIES FOR IMPROVEMENT OF SKIN | CUTA, COL14A1, EBP | HDAC1 755/4885HDAC2 1876/4885HDAC8 1371/4885 |
| US-20250339385-A1 | TOPICAL FORMULATION OF DIMETHYLCURCUMIN | DPM1, DIMT1, DSG1 | HDAC1 1146/4885HDAC2 1151/4885HDAC8 928/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | HDAC1 345/4885HDAC2 608/4885HDAC8 521/4885 |
| US-12303470-B2 | Method and composition for selective treatment of androgen receptors | AR, ARNT, SHBG | HDAC1 851/4885HDAC2 2542/4885HDAC8 1438/4885 |
| US-11802113-B2 | Substituted pyrazole compounds, compositions containing same, and use thereof | AR, NR5A1, SRD5A1 | HDAC1 144/4885HDAC2 282/4885HDAC8 197/4885 |
| US-12630883-B2 | Test method of dividing blastic plasmacytoid dendritic cell neoplasm (BPDCN) into subtypes | BCL3, BRD4, BCL6 | HDAC1 473/4885HDAC2 207/4885HDAC8 43/4885 |
| US-20100105644-A1 | BOTANICAL COMPOSITION FOR ENHANCED SKIN REPAIR AND USES THEREOF | CUTA, COL14A1, BACH1 | HDAC1 425/4885HDAC2 1794/4885HDAC8 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.